

Gemini Stock Analysis Report

Based on the analysis of the "Stock Detailed Analysis Report" for Torrent Pharmaceuticals (TORNTPHARM.NS) generated on 2026-01-24, here is my assessment as a Positional Equity Trader.

Step 1: Audit the Data

• Data Present:

- Daily Price Chart (3-Year) and Candlestick Analysis (Weekly/Daily/15m).
- Moving Averages (EMA 20, 50, 200).
- Relative Strength (RS) against Benchmark and Sector.
- Fundamental Snapshots (Revenue, Net Income, ROE, EPS trends).
- Technical Indicators: MACD, RSI, Bollinger Bands, Supertrend.
- Volume Analysis (Distribution days, Exhaustion signals).
- Analyst Estimates and Price Targets.

• Data Missing:

- Detailed Options Chain/Open Interest data (useful for identifying immediate resistance/support walls, though less critical for pure equity swing trading).
 - Specific news catalysts driving the recent 2.20% drop mentioned in the Trendlyne snapshot.
- **Confidence Level: High.** The report provides a comprehensive technical and fundamental view, allowing for a robust multi-timeframe analysis.

Step 2: Analyze the Setup

• Price Structure & Trend:

- **Primary Trend:** **Bullish.** The stock is trading above the 200 EMA (3589), indicating a long-term uptrend.
- **Intermediate Trend:** Weakening/Corrective. The price (3932) has slipped below the 20 EMA (3949) and is testing the 50 EMA (3857). The "Weakening Leader" classification confirms that while the stock is strong long-term, it is currently lagging the market momentum.

• Momentum:

- **MACD:** **Bearish.** The MACD line is below the signal line, and the histogram is negative, indicating downward pressure is currently dominant.
- **RSI:** Neutral (50.65). It has cooled off from overbought levels but hasn't found a hard floor yet.

• Support & Resistance:

- **Critical Support:** The confluence of the 50 EMA (3857) and the Supertrend value (3854). This is the "line in the sand."
- **Resistance:** The 20 EMA (3949) and the Upper Bollinger Band/Recent Highs (~4118).

• Volume:

- **Bearish** signals are present. Page 18 notes "Buying Exhaustion" and "Distribution Days" in Jan 2026. This suggests institutional profit-taking at higher levels.

• Valuation & Fundamentals:

- While growing, the "No Acceleration" flag and "Overvalued" PE check suggest the stock is priced for perfection. The analyst target of ~4080 implies limited upside (approx. 4%) from current levels unless a major breakout occurs.

Step 3: Formulate the Recommendation

Decision: NO.

Reasoning: Entering now is premature. The stock is in a short-term correction within a long-term uptrend. It is

Gemini Stock Analysis Report

currently "catching a falling knife" as it trades below the 20 EMA with bearish momentum (MACD). The reward-to-risk ratio is poor because immediate resistance (3950) is very close, and the stock hasn't successfully confirmed a bounce off the 50 EMA support yet. The upside to the consensus target is below your 5-15% threshold.

Conditional Plan (Wait for the Setup): We need to see the stock survive the test of the 50 EMA and reclaim short-term momentum.

- **Condition to Buy:** The price must close **above the 20 EMA** on the daily chart to confirm the correction is over and momentum has returned.
- **Entry Price: INR 3,965** (A close above 3950-3960 range).
- **Stop Loss: INR 3,840** (Just below the 50 EMA and Supertrend support level of 3854. If this breaks, the intermediate trend is broken).
- **Take Profit:**
 - **Target 1: INR 4,120** (Previous High/Upper Bollinger Band - approx 4% gain).
 - **Target 2: INR 4,350** (Blue sky breakout extension - approx 10% gain).

Note: If the stock closes below INR 3,850 before triggering the entry, cancel this setup as it will likely head toward the lower Bollinger Band (~3780) or deeper support.

News & Analyst Targets

As a stock research analyst at an investment firm, I have compiled the latest research and developments for **Torrent Pharmaceuticals (TORNTPHARM)** for the week ending **January 25, 2026**.

1. Latest News for TORNTPHARM (Week of Jan 19-25, 2026)

The ongoing week has been pivotal for Torrent Pharmaceuticals, headlined by a major acquisition closure and a significant regulatory win.

Completion of JB Chemicals Acquisition (Jan 21, 2026):

- Torrent Pharma successfully completed the acquisition of a controlling **46.39% stake in JB Chemicals & Pharmaceuticals**.
- The deal, valued at approximately **INR 11,917 crore**, grants Torrent "Promoter" status. This strategic move is expected to significantly strengthen its domestic branded generics portfolio and chronic therapy presence.
- **Management Overhaul:** Following the acquisition, a new leadership structure was announced for JB Chemicals. **Aman Mehta** has been appointed as the new Managing Director, while the previous CEO, Nikhil Chopra, will step down from the board but continue as CEO until March 2026.

USFDA Clearance for Dahej Facility (Jan 23, 2026):

- The company received a major compliance boost as the **USFDA inspection** at its **Dahej manufacturing facility** concluded with **Zero Observations**.
- This "clean chit" (Voluntary Action Indicated/No Action Indicated status effectively) removes regulatory overhang and validates the facility's adherence to global GMP standards, paving the way for future product approvals.

Stock Performance & Fundraising:

Gemini Stock Analysis Report

- **New 52-Week High:** Driven by the acquisition news, TORNTPHARM stock hit a new **52-week/all-time high** of approximately **INR 4,125** during the week (around Jan 19-20).
- **Debt Fund Raising:** The company is reportedly launching a debt issuance of nearly **INR 12,500 crore** (via bonds/NCDs) to finance the JB Chemicals deal.

2. Upgrade/Downgrade from Brokerages

Analyst sentiment remains largely positive, fueled by the synergistic potential of the JB Chemicals deal and the resolution of regulatory inspections.

- **Consensus View:** The analyst community has largely maintained a "**Buy**" or "**Accumulate**" stance. The successful closure of the JB Chemicals deal has solidified confidence in the company's inorganic growth strategy.
- **Recent Shifts:** There were no major *downgrades* reported this week. Most brokerages are currently reviewing the "Combined Entity" financials following the acquisition completion on Jan 21.
- **Previous Key Upgrades:** The stock continues to ride the momentum from late 2025 upgrades, such as **BofA Securities** (upgraded to Buy in Nov 2025) and **JPMorgan** (Overweight), which highlighted the company's superior return ratios and India-business strength.

3. Other News Impacting TORNTPHARM

- **Q3 Earnings Season:** While Q3 FY26 results are imminent (expected late January), the market focus this week was dominated by the acquisition news. The "clean" USFDA status acts as a strong precursor to the earnings call, likely mitigating concerns about pricing pressure in the US generics market.
- **Leadership Changes:** The appointment of Aman Mehta to lead the newly acquired JB Chemicals arm signals Torrent's intent to closely integrate and drive operational efficiencies in the new subsidiary immediately.

4. Latest Analyst Targets

Below is a summary of the latest available price targets and ratings from major brokerage firms and consensus estimates.

Brokerage / Source	Rating	Target Price (INR)	Date / Status
Trendlyne Consensus	Buy	4,080	Jan 25, 2026
Sharekhan	Buy	4,230	Late 2025 (Maintained)
BofA Securities	Buy	4,000	Nov 2025 (Upgrade)
JPMorgan	Overweight	3,800	Mid-2025 (Maintained)
Motilal Oswal	Neutral	3,770	Late 2025
ICICI Securities	Hold	3,530	Late 2025

Analyst Note: The current market price (CMP) is hovering around INR 3,932 - INR 4,020, trading near the consensus target. Analysts are expected to revise targets upward in the coming days to factor in the earnings accretion from the JB Chemicals acquisition.


Stock Detailed Analysis Report

TORNTPHARM.NS

Current Price: ₹3932.20

Generated: 2026-01-24 18:27

TORNTPHARM.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	7.15%	10.36%
Net Income	Yes	No	15.39%	34.98%
ROE	Yes	No	4.22%	24.48%
EPS	Yes	No	15.39%	34.98%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.77%	3.55%
Net Income	Yes	7.85%	6.98%
ROE	Yes	6.57%	7.65%
EPS	Yes	7.78%	6.01%

TORNTPHARM.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	57.0/100
:	

== RS RATIOS ==:

1M RS:	1.082 [Leader]
3M RS:	1.140 [Leader]
6M RS:	1.132 [Leader]
1Y RS:	1.268 [Strong]
:	


== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✗ Medium-term Lagging:	Not lagging
✗ Performance Improving:	Not improving


Relative Strength Analysis: TORNTPHARM.NS vs ^CNXPHARMA
Classification: Weakening Leader
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



TORNTPHARM.NS - EMA Crossover Summary

EMA 20:	3949.65
EMA 50:	3857.33
EMA 200:	3589.76
Trend Status:	Strong Uptrend
Golden Cross Date:	2022-07-29 00:00:00+05:30
Golden Cross Price:	1478.41

TORNTPHARM.NS EMA Crossover Analysis



TORNTPHARM.NS - Bollinger Bands Summary

Current Price:	3932.20
Upper Band:	4118.25
Middle Band (SMA 20):	3950.08
Lower Band:	3781.92
%B:	0.4468
Band Width:	0.0851
Status:	Lower Half
Signal:	None

TORNTPHARM.NS Bollinger Bands (20, 2) Analysis




TORNTPHARM.NS - Supertrend Summary

Status: UPTREND (Buy)

Supertrend Value: 3854.01

Signal Identified On: 2025-11-10

Supertrend Analysis for TORNTPHARM.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




TORNTPHARM.NS - MACD Summary

MACD Line:	48.10
Signal Line:	55.66
Histogram:	-7.55
Trend:	Bearish
Momentum:	Strengthening
Signal:	None

TORNTPHARM.NS Price






TORNTPHARM.NS MACD (12, 26, 9)



TORNTPHARM.NS - Volatility Squeeze Summary

BB Width:	0.0851
ATR:	90.0429
Total Signals:	32
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Price: 3869.80)
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Price: 3869.80)
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Price: 3869.80)
Signal 4:	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 3869.80)
Signal 5:	ATR Contraction at 2026-01-06 00:00:00+05:30 (Price: 3936.80)


TORNTPHARM.NS - Volatility Squeeze Analysis



TORNTPHARM.NS - RSI-Volume Summary

Current RSI:	50.65
Current Volume:	315842
Volume MA 20:	231351
Bullish Divergences:	1
Bearish Divergences:	1
Bullish Div 1:	Date: 2024-11-19 00:00:00+05:30, Price: 3065.07
Bearish Div 1:	Date: 2025-04-28 00:00:00+05:30, Price: 3328.68

TORNTPHARM.NS RSI-Volume Divergence Analysis





TORNTPHARM.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:	34 Signals Detected
:	
2025-11-11 [-]:	Climax Volume (Churning)
2025-11-12 [-]:	Distribution Day
2025-11-14 [-]:	Climax Volume (Churning)
2025-12-11 [+]:	Buying Exhaustion (Bearish Div)
2026-01-13 [-]:	Distribution Day

TORNTPHARM.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	3725.73	3932.2	2025-07-14
1 Day	UPTREND (Buy)	3854.01	3932.2	2025-11-10
15 Min	DOWNTREND (Sell)	3985.32	3932.2	2026-01-23

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bearish	Weakening	No Signal

TORNTPHARM.NS - 1 Week (Candlestick + EMAs)



TORNTPHARM.NS - 1 Day (Candlestick + EMAs)



TORNTPHARM.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - TORNTPHARM_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) [A](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [TORRENT PHARMACEUTICALS LTD.](#)

Torrent Pharmaceuticals Ltd. [ⓘ](#)

NSE: TORNTPHARM | BSE: 500420
Torrent Pharma Live Share Price Today, Share Analysis and Chart

■ ■ ■ Expensive Performer [ⓘ](#) ○ In 1 Starfolio Basket

3932.20 -88.30 (-2.20%)
[↑ New 52W High in past week](#)

328.2K NSE+BSE Volume
NSE 23 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score ⓘ 90.0 /100 High Financial Strength	Valuation Score ⓘ 26.7 /100 Expensive Valuation	Momentum Score ⓘ 58.7 /100 Technically Neutral	Analyst Price Target ⓘ 4,080 1Yr Price target upside is 4%
--	---	--	--

Expensive Performer These stocks are strong in quality but with mid-range technicals. Their valuations are expensive

[View Similar](#) ■ ■ ■ Embed DVM [ⓘ](#)

Check Before You Buy [VIEW FULL CHECKLIST](#)
High rank 16 Positive * 7 Negative
69.6% Pass in checklist

PE Valuation Check
Right Now [ⓘ](#) 1 Year Forward [ⓘ](#)
Overvalued -7.9% Undervalued 5.3%

IN SIGHT Torrent Pharma is overvalued at current PE, but undervalued on future earnings

Torrent Pharma Key Metrics

ROE Ann. % > High in industry	Broker Average Target > 1.16% upside	Market Capitalization > High in industry	Price to Book > High in industry
25.2	3,978	133,083.5	

[Preset Metrics](#) [Preset Metrics](#) [X](#)

DVM
Key Metrics
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile [X](#)

Trendlyne Snapshot - TORNTPHARM_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) [A](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [TORRENT PHARMACEUTICALS LTD.](#)

Torrent Pharmaceuticals Ltd. [ⓘ](#)

NSE: TORNTPHARM | BSE: 500420 [View Details](#)

■ ■ ■ Expensive Performer [①](#) In 1 Starfolio Basket

[Download real time STOCK REPORT](#)

3932.20 -88.30 (-2.20%)
↑ New 52W High in past week

328.2K NSE+BSE Volume
NSE 23 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News [Reports](#) Technicals Shareholding Deals Corporate Actions Alerts About

Torrent Pharma - TORNTPHARM - stock price prediction, stock forecast, target price, analyst ratings from 27 analysts

Torrent Pharma has a share price target of Rs 4080, revenue growth forecast of 13.3%, and profit growth estimate of 26.4% for FY26, based on top 27 analyst calls.

Torrent Pharma FORECASTER - Analyst Estimates [ⓘ](#)

[FORECASTER DASHBOARD →](#)

